August 15, 2018
This Week's Issue Sponsored by:
CDMO/CMO Watch: Cambrex, The Next End-to-End Provider in the Offing
By: Patricia Van Arnum, DCAT Editorial Director

Cambrex, a contract manufacture of small-molecule active pharmaceutical ingredients, is the latest contract manufacturer to establish an end-to-end-business model with its pending $425-million acquisition of Halo Pharmaceuticals, a CDMO of oral solids, liquids, creams, sterile and non-sterile ointments. So what is the industry impact of such a move?

Cambrex joins other contract providers, which have used acquisitions in recent years to build end-to-to end service models that provide both API and drug-product development and manufacturing, including Lonza, Catalent, Thermo Fisher’s Patheon, and Alcami among others. Is the end-to-end service model the way of the future?  
Brexit: Are Pharma Companies Prepared?
By: Patricia Van Arnum, DCAT Editorial Director

The UK’s withdrawal from the EU (i.e., Brexit) is scheduled to officially take place on March 29, 2019, but it is still open as to what a Brexit deal would be in terms of trade and custom policy. As negotiations and policy debates continue, what are the implications for the pharmaceutical industry?

The European Medicines Agency has been preparing for Brexit and recently conducted a survey to see if the pharmaceutical industry is ready. The survey showed that marketing authorization holders for more than half of the 694 centrally authorized products in the UK are on track with their regulatory planning to ensure that their marketing authorization remains valid post Brexit, but for 16% of these medicines with manufacturing sites located in the UK only, there are serious concerns that the necessary actions will not be carried out in time. This is a highlighted article from this year’s DCAT Value Chain Insights . 
VCI Headliners: Top Industry News
There will be no issue of  DCAT Value Chain Insights  on August 22, 29, or September 5 . The next issue of  DCAT Value Chain Insights   will be September 12.
About the Editor
Patricia Van Arnum has more than 20 years of experience as a business and science editor, covering the chemical, pharmaceutical, biopharmaceutical, and fine-chemicals industries. Ms. Van Arnum was Executive Editor of Pharmaceutical Technology from 2006 to 2014 and Executive Editor of ICIS Chemical Business and Chemical Market Reporter ( CMR ) from 1995 to 2005.
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .